z-logo
open-access-imgOpen Access
Targeted Metabolomics as a Tool in Discriminating Endocrine From Primary Hypertension
Author(s) -
Zoran Erlic,
Parminder Singh Reel,
Smarti Reel,
Laurence Amar,
Alessio Pecori,
Casper K. Larsen,
Martina Tetti,
Christina Pamporaki,
Cornelia Prehn,
Jerzy Adamski,
Aleksander Prejbisz,
Filippo Ceccato,
Carla Scaroni,
Matthias Kroiß,
Michael Conall Dennedy,
Jaap Deinum,
Katharina Langton,
Paolo Mulatero,
Martín Reincke,
Livia Lenzini,
AnnePaule GimenezRoqueplo,
Guillaume Assié,
Anne Blanchard,
MariaChristina Zennaro,
Emily Jefferson,
Felix Beuschlein
Publication year - 2020
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/clinem/dgaa954
Subject(s) - medicine , metabolomics , area under the curve , endocrine system , paraganglioma , endocrinology , bioinformatics , pathology , biology , hormone
Identification of patients with endocrine forms of hypertension (EHT) (primary hyperaldosteronism [PA], pheochromocytoma/paraganglioma [PPGL], and Cushing syndrome [CS]) provides the basis to implement individualized therapeutic strategies. Targeted metabolomics (TM) have revealed promising results in profiling cardiovascular diseases and endocrine conditions associated with hypertension.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom